Description

ACTIPRAZ-40 Tablets / Injections

Mode of Action
Esomeprazole magnesium reduces gastric acid secretion by inhibiting gastric enzyme H+, K+-ATPase (the proton pump) which is responsible for acid secretion by the parietal cells of the stomach.
Absorption of esomeprazole in healthy subjects results in peak plasma levels occurring 1 to 2 hours after dosing. The systemic bioavailability is 64% after a single 40 mg dose and 89% after repeated once-daily oral administration. The apparent volume of distribution at steady state in healthy subjects is around 0.22 L/kg body weight. Esomeprazole is 97% protein-bound and optically stable in vivo, with negligible inversion to the other isomer.
Pharmacodynamics
Esomeprazole accumulates in the acidic environment of the parietal cells after absorption, where it is converted into an active form. This active sulphenamide specifically binds the H+, K+-ATPase (proton pump), to block the final step in acid production, thus reducing gastric acidity. Esomeprazole is effective in the inhibition of both basal acid secretion and stimulated acid secretion.
Contraindication
Esomeprazole magnesium is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, and urticaria.

Better to compare drugs of the class
Esomeprazole 40 mg provides more effective acid control than omeprazole in patients with symptoms of gastroesophageal reflux disease